Drugs with Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
✉ Email this page to a colleague
Drugs with Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | Dosage |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scinopharm Taiwan | BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 216912-001 | Sep 26, 2023 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | ||||
Mylan Labs Ltd | BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 205160-001 | Oct 31, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | ||||
Waverley Pharma Inc | BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 211898-001 | Oct 11, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration | >Dosage |